Saturday 17 October 2026
Export NBIX’s income statement to Excel — free account
Neurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 31.2% and free cash flow grew 43.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.
135.71
1.24
−0.91%
Follow NBIX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 22.09% | 22.50% | 16.38% | 14.96% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
6 | 7 | 7 | 5 | |
| 15.26% | 15.56% | 11.46% | 10.97% | ||
ROIC |
15.04% | 23.58% | 21.83% | 18.21% | |
Return on Tangible Assets |
82.66% | 39.44% | 25.61% | 26.46% | |
Average Days of Receivables |
95.96 | 90.37 | 87.64 | 99.05 | |
Free Cash Flow per Share |
8.62 | 8.27 | 7.52 | 5.97 | |
Free Cash Flow |
870.40 | 831.30 | 748.70 | 593.10 | |
Capital Expenditures |
(27.70) | (32.40) | (34.00) | (43.70) | |
| Other line items | |||||
Cash ROIC |
21.32% | 17.60% | 15.82% | 14.40% | |
Accounts Receivable Turnover |
4.55 | 4.83 | 4.91 | 4.44 | |
Accounts Payable Turnover |
0.11 | 0.09 | 0.09 | 0.09 | |
Inventory Turnover |
0.86 | 0.92 | 0.82 | 0.74 | |
Average Days of Payables |
4,238.93 | 4,976.10 | 4,723.98 | 4,982.93 | |
Days of Inventory on Hand |
546.45 | 415.21 | 483.40 | 590.99 | |
Tax Rate |
(0.25) | (0.29) | (0.32) | (0.32) | |
Research and Development Expense of Revenue |
33.52% | 33.80% | 35.51% | 35.15% | |
Selling, General and Administrative Expense of Revenue |
40.06% | 38.62% | 40.42% | 42.58% | |
Share Based Compensation of Revenue |
6.95% | 7.17% | 7.62% | 8.41% | |
Interest Coverage |
92.42 | — | — | — | |
Operating CF/Net income |
1.27 | 1.29 | 1.64 | 1.49 | |
Depreciation/Fixed assets |
0.42 | 0.19 | 0.19 | 0.04 | |
Capex/Depreciation |
(0.74) | (1.89) | (1.95) | (12.49) | |
Revenue per Share |
33.41 | 30.87 | 28.75 | 26.99 | |
Operating CF per Share |
8.89 | 8.59 | 7.87 | 6.41 | |
Capex per Share |
(0.27) | (0.32) | (0.34) | (0.44) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.02 |
Columns are period end dates